Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites
Biomolecules
2012-10-12 v1 Subcellular Processes
Abstract
HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, and is an attractive target for new anti-HIV drugs. Integrase is an enzyme produced by a retrovirus (such as HIV) that enables its genetic material to be integrated into the DNA of the infected cell. Raltegravir and Elvitegravir are two important drugs against integrase.
Cite
@article{arxiv.1210.3154,
title = {Docking Studies on HIV Integrase Inhibitors Based On Potential Ligand Binding Sites},
author = {Subhomoi Borkotoky},
journal= {arXiv preprint arXiv:1210.3154},
year = {2012}
}
Comments
9 pages, 6 tables